Cost-Effectiveness Standards in the UK Lead to Restrictions in Patient Access to Cancer Therapies

07.11.14 | By

The debate over the cost and value of innovative medicines has prompted some to make renewed calls for use of a cost-effectiveness or similar standard in the U.S. One example of this was highlighted in a recent column by Ed Silverman at the Wall Street Journal.

Consumers Need Safe Disposal Options, Not Mandates

07.10.14 | By

Today, Mark Chenoweth of Washington Legal Foundation published a great blog in Forbes (and a similar LTE in San Francisco Chronicle) about upcoming oral arguments for our litigation in Alameda County regarding safe disposal.

Negotiators Push Ahead on TPP in Canada

07.08.14 | By

Today, the countries participating in the Trans-Pacific Partnership (TPP) agreement begin yet another round of negotiations in Ottawa, Canada. The TPP is a trade deal currently being negotiated between the U.S. and 11 countries in the Pacific Rim region, including Canada and Japan. The agreement is predicted to increase U.S. exports by $125 billion and help transform how business is conducted in the global economy.

STEM Saves Lives Remarks

Week in Review: Celebrating Patient Health

07.03.14 | By

Before we leave to celebrate the holiday weekend, we wanted to talk about the latest happenings in the biopharmaceutical industry and the importance of celebrating patients.

Medicines in Development for Older Americans

07.03.14 | By

As overall life expectancy continues to grow, so does the number of older Americans, the majority of whom have at least one chronic disease. Chronic diseases not only impact our loved ones living with them, but our families as well and cost the health care system billions of dollars. Prospective medicines currently in the pipeline hold promise to improve health outcomes and provide cost savings.

Rx Response Benefits

07.01.14 | By

We all know that it only takes one storm to have severe impact, which is why we wanted to remind you that Rx Response stands ready to support any disaster that has wide-spread impact to pharmaceutical supply, and that all of our services are offered at no cost to government partners.

Week in Review: Ensuring Patients Have Access to Needed Treatments

06.27.14 | By

Biopharmaceutical research and development (R&D) is fueled by innovative minds with an eye toward the future. It has provided patients around the world with treatments to help them live healthier, more productive lives. This week, we focused on the ways in which innovation continues to help patients thrive and the unfortunate roadblocks that often hinder patient access to life-changing medicines.

ICYMI: Insurer: “Can drugs as expensive as these really be cost-effective? The answer is yes.”

06.25.14 | By

The focus in recent weeks on the cost of a new cure for Hepatitis C has largely ignored the long-term value it provides to patients and the health care system broadly, including helping to prevent expensive hospitalizations and costly medical procedures, such as liver transplants.

Restricting Access to Medicines At the Expense of Patients Warrants a Candid Conversation

06.23.14 | By

It has become increasingly clear in recent weeks that far too many patients simply cannot access innovative medicines that help treat costly chronic diseases. While more Americans now have health care coverage under the Affordable Care Act (ACA), they still face insurmountable barriers to access that hinder our collective efforts to prevent, manage, and cure these conditions.


Subscribe to RSS - Opinion